Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived Anti-leukemia CTLs for Relapse Prevention in Pediatric HSCT
NCT06865352Phase 2Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Bone Marrow HSCs, HLA-independent TCR-T, Allogeneic CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of hematopoietic stem cell transplantation donor leukemia-specific cytotoxic T-cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), sponsored by IRCCS San Matteo Foundation. Started Feb 2021; status: completed.
02
Drugs
hematopoietic stem cell transplantation donor leukemia-specific cytotoxic T-cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06865352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865352.